State Street Corp Acurx Pharmaceuticals, Inc. Transaction History
State Street Corp
- $2.41 Trillion
- Q3 2024
A detailed history of State Street Corp transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, State Street Corp holds 43,466 shares of ACXP stock, worth $72,588. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,466
Previous 43,466
-0.0%
Holding current value
$72,588
Previous $97,000
15.46%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ACXP
# of Institutions
26Shares Held
1.25MCall Options Held
9.3KPut Options Held
9.7K-
Vanguard Group Inc Valley Forge, PA529KShares$884,0120.0% of portfolio
-
Prospect Financial Services LLC Melville, NY295KShares$492,7750.35% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$244,6550.0% of portfolio
-
Morgan Stanley New York, NY46.2KShares$77,1550.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC44.8KShares$74,7820.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $19.3M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...